{
    "Trade/Device Name(s)": [
        "ADVIA Centaur CEA assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K200215",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981478"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHX"
    ],
    "Summary Letter Date": "April 13, 2020",
    "Summary Letter Received Date": "January 28, 2020",
    "Submission Date": "January 27, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Carcinoembryonic antigen (CEA)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP",
        "ADVIA Centaur XPT"
    ],
    "Method(s)/Technology(ies)": [
        "Sandwich immunoassay",
        "Direct chemiluminescent"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur CEA assay, a direct chemiluminescent immunoassay for quantitative measurement of CEA in serum and plasma using ADVIA Centaur XP/XPT systems.",
    "Indications for Use Summary": "For in vitro diagnostic use in the quantitative measurement of carcinoembryonic antigen (CEA) in serum and plasma (EDTA and lithium heparin) to aid in the management of cancer patients in whom changing concentrations of CEA are observed using the ADVIA Centaur XP and ADVIA Centaur XPT systems.",
    "fda_folder": "Immunology"
}